

Georg Pilz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1803638/georg-pilz-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

363
citations

10
h-index

19
g-index

30
ext. papers

463
ext. citations

5.9
avg, IF

2.87
L-index

#	Paper	IF	Citations
23	The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF. <i>Fluids and Barriers of the CNS</i> , 2021 , 18, 40	7	1
22	Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction. <i>Fluids and Barriers of the CNS</i> , 2020 , 17, 7	7	6
21	Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases. <i>Journal of Neuroimmunology</i> , 2020 , 338, 577087	3.5	2
20	Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study. <i>Journal of Clinical Virology</i> , 2020 , 127, 104340	14.5	5
19	Cerebrospinal fluid CXCL13 indicates disease course in neuroinfection: an observational study. <i>Journal of Neuroinflammation</i> , 2019 , 16, 13	10.1	4
18	Epidemiology of status epilepticus in adults: A population-based study on incidence, causes, and outcomes. <i>Epilepsia</i> , 2019 , 60, 53-62	6.4	67
17	Factor VII deficiency in major artery occlusion stroke. <i>American Journal of Hematology</i> , 2018 , 93, 843-845	7.1	1
16	Intravenous brivaracetam in status epilepticus: A retrospective single-center study. <i>Epilepsia</i> , 2018 , 59 Suppl 2, 228-233	6.4	35
15	Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: A single-center audit of 30 patients. <i>Epilepsia</i> , 2018 , 59 Suppl 2, 234-242	6.4	24
14	From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. <i>Clinical Immunology</i> , 2017 , 176, 87-93	9	6
13	Coronary angiography as a rare cause for incomplete anterior spinal artery syndrome. <i>Journal of Neurology</i> , 2017 , 264, 799-801	5.5	
12	Critical Illness in Patients with Multiple Sclerosis: A Matched Case-Control Study. <i>PLoS ONE</i> , 2016 , 11, e0155795	3.7	13
11	Panitumumab-Associated Encephalopathy after Accidental Intra-arterial Application through Dislocated Central Venous Access Device. <i>Frontiers in Neurology</i> , 2016 , 7, 196	4.1	1
10	(S)-Ketamine in Refractory and Super-Refractory Status Epilepticus: A Retrospective Study. <i>CNS Drugs</i> , 2016 , 30, 869-76	6.7	37
9	Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukoencephalopathy with an excellent outcome. <i>Clinical and Experimental Neuroimmunology</i> , 2015 , 6, 172-174	0.4	0
8	Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 21832-45	6.3	7
7	Tumefactive MS lesions under fingolimod: a case report and literature review. <i>Neurology</i> , 2013 , 81, 1654-68	6.5	61

6	Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e31784	3.7	18
5	Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. <i>Journal of Neuroimmunology</i> , 2011 , 234, 148-54	3.5	24
4	Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. <i>Drug Discovery Today</i> , 2011 , 16, 8-21	8.8	7
3	Invasive aspergillosis presenting with a painless complete ophthalmoplegia. <i>Clinical Neurology and Neurosurgery</i> , 2010 , 112, 85-7	2	7
2	Modern multiple sclerosis treatment - what is approved, what is on the horizon. <i>Drug Discovery Today</i> , 2008 , 13, 1013-25	8.8	15
1	Absent reduction by HIV protease inhibitors of <i>Candida albicans</i> adhesion to endothelial cells. <i>Mycoses</i> , 2007 , 50, 172-7	5.2	22